Cell composition and methods of making the same

1. A method of making a composition comprising homogenous isolated human adherent placental cells that have been passaged in vitro at least two times, comprising:

(a) contacting said cells with a first solution comprising dextran and human serum albumin (HSA) to form a cell-containing solution;

(b) filtering out macro cell clumps from the cell-containing solution;

(c) diluting said cells to no more than about 10±3×10 6 cells per milliliter with a second solution comprising dextran, dimethylsulfoxide (DMSO), and HSA; and

(d) cryopreserving said cells after step (c), thereby making a composition comprising isolated human adherent placental cells.

2. The method of claim 1 , wherein said dextran is dextran 40.

3. The method of claim 1 , wherein said second solution comprises about 5.5% dextran 40.

4. The method of claim 1 , wherein said second solution comprises about 10% HSA.

5. The method of claim 1 , wherein said second solution comprises about 2.5% DMSO.

6. The method of claim 1 , wherein said second solution comprises about 7.5% to about 9% dextran.

7. The method of claim 1 , wherein said composition comprising cells comprises about 1.0±0.3×10 6 cells per milliliter to about 5.0±1.5×10 6 cells per milliliter.

8. A method of making a composition comprising cells, comprising:

(a) suspending a plurality of homogenous isolated human adherent placental cells, which have been passaged in vitro at least two times, in a 5.5% dextran 40, 10% HSA solution to form a cell-containing solution;

(b) filtering the cell-containing solution through a 70 μM filter to filter out macro cell clumps from the cell-containing solution;

(c) diluting the cell-containing solution in 5.5% dextran 40, 10% HSA, and 5% DMSO to no more than about 10±3×10 6 cells/mL;

(d) cryopreserving the cells; and

(e) thawing the cells

to produce said composition comprising cells.

9. A method of making a composition comprising cells, comprising:

(a) centrifuging a plurality of homogenous isolated human adherent placental cells, which have been passaged in vitro at least two times, to collect the cells;

(b) resuspending the cells in 5.5% dextran 40;

(c) centrifuging the cells to collect the cells;

(d) resuspending the cells in a 5.5% dextran 40 solution that comprises 10% HSA to form a cell-containing solution;

(e) filtering the cell-containing solution through a 70 μM to 100 μM filter to filter out macro cell clumps from the cell-containing solution;

(f) diluting the cell-containing solution in 5.5% dextran 40, 10% HSA, and 5% DMSO to no more than about 10±3×10 6 cells/mL;

(g) cryopreserving the cells; and

(h) thawing the cells

to produce said composition comprising cells.

10. A method of making a composition comprising homogenous isolated human adherent placental cells, comprising:

(a) providing a plurality of homogenous isolated human adherent placental cells, which have been passaged in vitro at least two times, in a solution comprising 5.5% dextran 40 and 10% HSA to form a solution comprising isolated human adherent placental cells;

(b) filtering said solution comprising homogenous isolated human adherent placental cells to filter out macro cell clumps from the cell-containing solution to produce filtered isolated human adherent placental cells;

(c) diluting said filtered isolated human adherent placental cells with an amount of a solution comprising 5.5% dextran 40, 10% HSA and 5% dimethylsulfoxide (DMSO) sufficient to bring said filtered isolated human adherent placental cells to about 10±3×10 6 cells per milliliter;

(d) diluting said isolated human adherent placental cells with 10% dextran 40 at a ratio of about 1:1 to about 1:11 isolated human adherent placental cells:dextran 40 to produce said composition;

(e) cryopreserving the cells.

11. The method of claim 1 , wherein said filter is a 70 μM filter.

12. The method of claim 1 , wherein said filter is a 100 μM filter.

13. The method of claim 1 , wherein said isolated human adherent placental cells are CD10 + , CD34 − and CD105 + .

14. The method of claim 13 , wherein said CD10 + , CD34 − and CD105 + cells are CD200 + .

15. The method of claim 14 , wherein said CD10 + , CD34 − , CD105 + and CD200 + cells are either CD45 − or CD90 + .

16. The method of claim 14 , wherein said CD10 + , CD34 − , CD105 + and CD200 + cells are CD45 − and CD90+.

17. The method of claim 1 , further comprising concentrating the composition comprising cells to about 5×10 6 cells per milliliter to 1×10 8 cells per milliliter.

18. The method of claim 17 , further comprising subcutaneously administering the composition comprising cells to a subject.

19. The method of claim 8 , further comprising diluting the com position comprising cells after step (e) 1:1 to 1:11 with 10% dextran 40.

20. The method of claim 9 , further comprising diluting the composition comprising cells after step (h) 1:1 to 1:11 with 10% dextran 40.

21. The method of claim 1 , wherein said filter is a 70 μM to 100 μM filter.

22. The method of claim 1 , wherein said second solution comprises 5.0% dextran, 10% HSA, and 2.5% DMSO.